| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 63 | 2024 | 2138 | 4.990 |
Why?
|
| Waldenstrom Macroglobulinemia | 13 | 2023 | 273 | 2.930 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 35 | 2024 | 6550 | 1.630 |
Why?
|
| Transplantation, Autologous | 29 | 2024 | 1914 | 1.010 |
Why?
|
| Lymphoma, B-Cell | 2 | 2021 | 895 | 0.770 |
Why?
|
| Thalidomide | 7 | 2019 | 569 | 0.750 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2023 | 15862 | 0.740 |
Why?
|
| Pyrazines | 6 | 2019 | 495 | 0.660 |
Why?
|
| Immunotherapy, Active | 1 | 2018 | 46 | 0.630 |
Why?
|
| Dexamethasone | 15 | 2023 | 1450 | 0.620 |
Why?
|
| Vaccines, DNA | 1 | 2018 | 105 | 0.600 |
Why?
|
| Antibodies, Monoclonal | 8 | 2022 | 4367 | 0.600 |
Why?
|
| Plasmacytoma | 4 | 2021 | 111 | 0.590 |
Why?
|
| Boronic Acids | 5 | 2014 | 362 | 0.550 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2013 | 101 | 0.530 |
Why?
|
| Bortezomib | 12 | 2022 | 543 | 0.510 |
Why?
|
| Antineoplastic Agents | 15 | 2022 | 14289 | 0.490 |
Why?
|
| Peripheral Nervous System Diseases | 5 | 2015 | 393 | 0.470 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2013 | 31 | 0.460 |
Why?
|
| Rituximab | 7 | 2023 | 1528 | 0.460 |
Why?
|
| Myeloid Differentiation Factor 88 | 4 | 2021 | 155 | 0.450 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 1555 | 0.430 |
Why?
|
| Paraproteins | 3 | 2021 | 39 | 0.430 |
Why?
|
| Chromosome Aberrations | 8 | 2024 | 1960 | 0.390 |
Why?
|
| Interleukin-6 | 2 | 2013 | 1038 | 0.390 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 447 | 0.370 |
Why?
|
| Hepatitis B | 2 | 2023 | 258 | 0.370 |
Why?
|
| Melphalan | 7 | 2020 | 834 | 0.360 |
Why?
|
| Humans | 85 | 2024 | 261506 | 0.340 |
Why?
|
| Leukemia, Plasma Cell | 2 | 2019 | 42 | 0.340 |
Why?
|
| Transplantation Conditioning | 8 | 2020 | 2238 | 0.330 |
Why?
|
| Aged | 43 | 2023 | 70117 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 10035 | 0.330 |
Why?
|
| Middle Aged | 45 | 2023 | 86204 | 0.310 |
Why?
|
| Electrocardiography | 1 | 2013 | 1145 | 0.310 |
Why?
|
| POEMS Syndrome | 2 | 2018 | 22 | 0.290 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 697 | 0.280 |
Why?
|
| Retrospective Studies | 30 | 2024 | 37905 | 0.280 |
Why?
|
| Adult | 34 | 2023 | 77950 | 0.260 |
Why?
|
| Maintenance Chemotherapy | 3 | 2021 | 202 | 0.260 |
Why?
|
| Virus Activation | 2 | 2023 | 228 | 0.240 |
Why?
|
| Male | 44 | 2023 | 123000 | 0.230 |
Why?
|
| Smoldering Multiple Myeloma | 1 | 2023 | 9 | 0.230 |
Why?
|
| Immunoglobulin M | 2 | 2021 | 347 | 0.230 |
Why?
|
| Treatment Outcome | 26 | 2023 | 32848 | 0.230 |
Why?
|
| Oligopeptides | 4 | 2022 | 429 | 0.230 |
Why?
|
| Heterocyclic Compounds | 2 | 2022 | 119 | 0.230 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2018 | 216 | 0.230 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2023 | 31 | 0.230 |
Why?
|
| Stem Cell Transplantation | 5 | 2023 | 1360 | 0.220 |
Why?
|
| Recurrence | 8 | 2019 | 4758 | 0.220 |
Why?
|
| Female | 44 | 2023 | 141928 | 0.220 |
Why?
|
| Salvage Therapy | 5 | 2019 | 2054 | 0.210 |
Why?
|
| Translocation, Genetic | 4 | 2023 | 1245 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6207 | 0.200 |
Why?
|
| Quinazolines | 1 | 2006 | 923 | 0.190 |
Why?
|
| Aged, 80 and over | 17 | 2023 | 29902 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 4 | 2022 | 266 | 0.190 |
Why?
|
| Prognosis | 16 | 2023 | 21713 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 5178 | 0.190 |
Why?
|
| Amyloidosis | 2 | 2016 | 176 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2021 | 3552 | 0.180 |
Why?
|
| Immunoglobulin A | 2 | 2021 | 237 | 0.180 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2017 | 129 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 4757 | 0.170 |
Why?
|
| Busulfan | 2 | 2020 | 764 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2019 | 45 | 0.170 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 269 | 0.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2023 | 2232 | 0.170 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 39 | 0.160 |
Why?
|
| Pain | 4 | 2019 | 1658 | 0.160 |
Why?
|
| Myeloablative Agonists | 2 | 2018 | 384 | 0.160 |
Why?
|
| Disease-Free Survival | 10 | 2021 | 10001 | 0.160 |
Why?
|
| Chemokine CCL20 | 1 | 2018 | 39 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2019 | 272 | 0.160 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 669 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2019 | 402 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 588 | 0.150 |
Why?
|
| Antigens | 1 | 2018 | 292 | 0.150 |
Why?
|
| Diploidy | 1 | 2017 | 114 | 0.150 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 61 | 0.150 |
Why?
|
| Autografts | 3 | 2023 | 165 | 0.140 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 30 | 0.140 |
Why?
|
| Disease Progression | 6 | 2023 | 6682 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 4320 | 0.140 |
Why?
|
| Vincristine | 2 | 2018 | 1511 | 0.140 |
Why?
|
| Cyclophosphamide | 3 | 2019 | 3001 | 0.140 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 1021 | 0.140 |
Why?
|
| Orbital Neoplasms | 1 | 2018 | 224 | 0.140 |
Why?
|
| Prednisone | 1 | 2018 | 984 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 806 | 0.140 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 295 | 0.130 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2016 | 109 | 0.130 |
Why?
|
| Janus Kinase 1 | 1 | 2016 | 121 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2019 | 739 | 0.130 |
Why?
|
| Oxazines | 1 | 2015 | 43 | 0.130 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 231 | 0.130 |
Why?
|
| Electroacupuncture | 1 | 2014 | 35 | 0.120 |
Why?
|
| Benzamides | 1 | 2019 | 1832 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 419 | 0.120 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.120 |
Why?
|
| Fingers | 1 | 2014 | 120 | 0.120 |
Why?
|
| Remission Induction | 4 | 2019 | 3569 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2016 | 731 | 0.120 |
Why?
|
| Plasma Cells | 3 | 2023 | 192 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 2843 | 0.110 |
Why?
|
| ErbB Receptors | 2 | 2016 | 2295 | 0.110 |
Why?
|
| Hypesthesia | 1 | 2013 | 22 | 0.110 |
Why?
|
| Hepatitis B Antibodies | 2 | 2023 | 58 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 589 | 0.110 |
Why?
|
| Propensity Score | 3 | 2021 | 750 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 749 | 0.110 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 84 | 0.110 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 2638 | 0.110 |
Why?
|
| Immunologic Factors | 2 | 2014 | 649 | 0.110 |
Why?
|
| Survival Rate | 7 | 2019 | 12221 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 1249 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 249 | 0.110 |
Why?
|
| Transcriptome | 1 | 2021 | 1859 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 5159 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 2594 | 0.100 |
Why?
|
| Vaccination | 1 | 2018 | 1123 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 242 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1870 | 0.100 |
Why?
|
| Cyclin D2 | 1 | 2010 | 40 | 0.100 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 217 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 3472 | 0.100 |
Why?
|
| Infection Control | 1 | 2013 | 270 | 0.100 |
Why?
|
| Spinal Fractures | 1 | 2012 | 132 | 0.100 |
Why?
|
| Guanidines | 1 | 2010 | 60 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 347 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2016 | 691 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 610 | 0.090 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 14889 | 0.090 |
Why?
|
| Phenols | 1 | 2010 | 107 | 0.090 |
Why?
|
| Proteins | 1 | 2018 | 1963 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 901 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 527 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 1121 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 544 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2009 | 1391 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2330 | 0.090 |
Why?
|
| Bendamustine Hydrochloride | 2 | 2023 | 107 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 1265 | 0.080 |
Why?
|
| Signal Transduction | 5 | 2018 | 11965 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 388 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 5319 | 0.080 |
Why?
|
| Pyridines | 1 | 2015 | 1244 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 587 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 12873 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1756 | 0.070 |
Why?
|
| Antigens, CD34 | 2 | 2022 | 593 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2013 | 786 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2022 | 9180 | 0.070 |
Why?
|
| Imidazoles | 1 | 2012 | 999 | 0.070 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2018 | 278 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3821 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2015 | 2358 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 1290 | 0.070 |
Why?
|
| Cell Survival | 3 | 2018 | 3045 | 0.070 |
Why?
|
| RNA | 1 | 2010 | 1013 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2009 | 1248 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8865 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 2054 | 0.060 |
Why?
|
| Neutropenia | 2 | 2019 | 968 | 0.060 |
Why?
|
| Sensory Thresholds | 2 | 2014 | 68 | 0.060 |
Why?
|
| Quality of Life | 2 | 2019 | 4532 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2011 | 1824 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 11538 | 0.060 |
Why?
|
| Young Adult | 6 | 2023 | 21445 | 0.060 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 10331 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 14551 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2018 | 1313 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1664 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2017 | 6100 | 0.050 |
Why?
|
| Boron Compounds | 1 | 2022 | 59 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2022 | 141 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2023 | 369 | 0.050 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4298 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 864 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2016 | 1869 | 0.050 |
Why?
|
| Apoptosis | 4 | 2018 | 7591 | 0.050 |
Why?
|
| Glycine | 1 | 2022 | 289 | 0.050 |
Why?
|
| Time Factors | 4 | 2017 | 12926 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 63 | 0.040 |
Why?
|
| Thiadiazoles | 1 | 2019 | 47 | 0.040 |
Why?
|
| Carmustine | 1 | 2019 | 214 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 244 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2018 | 61 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 978 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 13658 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2018 | 77 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2016 | 3536 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 2576 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 452 | 0.040 |
Why?
|
| Adenine | 1 | 2021 | 631 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2019 | 3005 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 1 | 2017 | 56 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 587 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2014 | 2292 | 0.040 |
Why?
|
| Abnormal Karyotype | 1 | 2017 | 100 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2018 | 392 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2017 | 61 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 333 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2015 | 2084 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 308 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 1819 | 0.040 |
Why?
|
| Protein Domains | 1 | 2018 | 314 | 0.040 |
Why?
|
| Karyotype | 1 | 2017 | 234 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2010 | 5270 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2016 | 141 | 0.040 |
Why?
|
| Myeloma Proteins | 1 | 2015 | 28 | 0.030 |
Why?
|
| Paraproteinemias | 1 | 2015 | 61 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 905 | 0.030 |
Why?
|
| Piperidines | 1 | 2021 | 1035 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 437 | 0.030 |
Why?
|
| Syk Kinase | 1 | 2015 | 56 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2018 | 575 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2016 | 251 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 2283 | 0.030 |
Why?
|
| Skin Temperature | 1 | 2014 | 32 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 589 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2021 | 3203 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 388 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Sensorimotor Cortex | 1 | 2014 | 22 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2014 | 75 | 0.030 |
Why?
|
| Cold Temperature | 1 | 2014 | 121 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Biomarkers | 2 | 2016 | 5047 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 5395 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 73 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3230 | 0.030 |
Why?
|
| Animals | 5 | 2018 | 59536 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2014 | 245 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2014 | 281 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2013 | 84 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 289 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 810 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 2483 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 212 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 980 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 7222 | 0.030 |
Why?
|
| Cytarabine | 1 | 2019 | 1973 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 4938 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 1053 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1589 | 0.030 |
Why?
|
| Kyphoplasty | 1 | 2012 | 9 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 702 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 2864 | 0.030 |
Why?
|
| Vertebroplasty | 1 | 2012 | 24 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2017 | 1442 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 663 | 0.030 |
Why?
|
| Everolimus | 1 | 2014 | 415 | 0.030 |
Why?
|
| Primary Graft Dysfunction | 1 | 2012 | 34 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 168 | 0.030 |
Why?
|
| Fractures, Compression | 1 | 2012 | 42 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 1544 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 854 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 1408 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 1546 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2018 | 1549 | 0.020 |
Why?
|
| Consolidation Chemotherapy | 1 | 2012 | 155 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 37 | 0.020 |
Why?
|
| MafB Transcription Factor | 1 | 2010 | 12 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2015 | 1681 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 3842 | 0.020 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 72 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Fatigue | 1 | 2017 | 1239 | 0.020 |
Why?
|
| Tretinoin | 1 | 2013 | 623 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4143 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 5114 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1008 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 367 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 953 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 814 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 3639 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 8873 | 0.020 |
Why?
|
| Mice | 3 | 2018 | 34495 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 630 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 392 | 0.020 |
Why?
|
| Vidarabine | 1 | 2014 | 1341 | 0.020 |
Why?
|
| Filgrastim | 1 | 2009 | 191 | 0.020 |
Why?
|
| Benzylamines | 1 | 2009 | 105 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 1489 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 1294 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 5377 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 1544 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 566 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2009 | 152 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2012 | 7226 | 0.020 |
Why?
|
| United States | 1 | 2006 | 15433 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 344 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 1062 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 3443 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2010 | 771 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 1077 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1503 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 4053 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 870 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 4971 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 3343 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3438 | 0.020 |
Why?
|
| Risk Factors | 2 | 2017 | 17523 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2171 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2508 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 6311 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3033 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 4314 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 2944 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 1375 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3570 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2216 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4892 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 4917 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 3719 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5539 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2927 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3251 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 9244 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2015 | 3518 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 3154 | 0.010 |
Why?
|
| Incidence | 1 | 2012 | 5673 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 5687 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 4988 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 31252 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 7551 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 6915 | 0.010 |
Why?
|